Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Has Consensus Target Price of $19.75

Satellos Bioscience Inc. (NASDAQ:MSLE) has earned an average rating of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $19.75.

A number of research analysts recently commented on MSLE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Friday, August 7th. Wells Fargo & Company set a $18.00 target price on Satellos Bioscience in a research report on Thursday, July 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Satellos Bioscience in a research note on Monday, August 17th.

Satellos Bioscience Stock Down 1.2%

MSLE stock opened at $8.50 on Monday. The company has a market capitalization of $180.37 million, a P/E ratio of -4.43 and a beta of 1.53. The company has a 50-day simple moving average of $9.48 and a 200 day simple moving average of $7.97. Satellos Bioscience has a fifty-two week low of $5.30 and a fifty-two week high of $13.39.

Satellos Bioscience (NASDAQ:MSLE) last released its earnings results on Thursday, August 13th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.18). Equities analysts anticipate that Satellos Bioscience will post -1.86 EPS for the current year.

Institutional Investors Weigh In On Satellos Bioscience

A hedge fund recently raised its position in Satellos Bioscience stock. AWM Investment Company Inc. boosted its stake in shares of Satellos Bioscience Inc. (NASDAQ:MSLE) by 41.9% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 305,000 shares of the company’s stock after purchasing an additional 90,000 shares during the period. AWM Investment Company Inc. owned about 1.46% of Satellos Bioscience worth $2,338,000 at the end of the most recent reporting period.

About Satellos Bioscience

Satellos Bioscience Inc is a biotechnology company focused on developing regenerative medicines for conditions involving skeletal muscle damage, degeneration, or impaired repair. The company’s research is based on the role of muscle stem cells, also known as satellite cells, in maintaining and regenerating muscle tissue.

Satellos’ lead product candidate is SAT-3247, an orally administered small-molecule therapy designed to enhance the activation and function of muscle stem cells. The company is evaluating this approach for potential use in diseases characterized by progressive muscle weakness, including Duchenne muscular dystrophy and other muscle disorders.

Satellos Bioscience is headquartered in Vancouver, British Columbia, and is developing its therapies for international pharmaceutical and biotechnology markets.